Evolus Q2 revenue rises 21%, lifts 2026 outlook

Evolus raised its 2026 net revenue guidance to $330 million-$337 million, from $327 million-$337 million.

The company also lifted its 2026 adjusted gross profit margin outlook to 67.0%-67.5%, from 65.5%-67.0%.

Evolus reaffirmed its 2026 low- to mid-single-digit adjusted EBITDA margin outlook.

Evolus said second-quarter revenue rose 21% year over year, driven by market share gains.

The US injectable aesthetics company said it delivered its third consecutive quarter of positive adjusted EBITDA, reflecting improved operating leverage.

Result drivers

• Product growth - Double-digit growth for Jeuveau and increased adoption of Evolysse drove revenue gains, according to CEO David Moatazedi.
• Consumer demand - Healthy consumer demand, increased customer penetration, and strong reorder behavior supported commercial execution.
• Portfolio expansion - The launch of the Estyme collection in Europe and expansion into Canada, Australia, and New Zealand broadened the international growth opportunity.

Key details